For the first quarter of 2009, total sales were $5.38 billion, a decrease of 8%, compared to $5.82 billion in the same quarter of 2008.
Richard Clark, chairman, president and CEO of Merck & Company, said: “Our first-quarter results in part reflect the impact of the difficult global economy on patients, providers and payors, but we remain on track to meet our full-year earnings guidance.
“We believe our planned merger with Schering-Plough will accelerate Merck’s transformation into a global healthcare leader built for sustainable growth and success. Together we will have a formidable pipeline, an expanded product portfolio, a broader global presence, and the best talent in the industry. The new Merck will have increased financial strength and enhanced capabilities focused on breakthrough R&D.”